You are here

Article Text

Article menu
Download PDFPDF
Drug therapy
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1
  1. S Sakaguchi1,
  2. F Garcia-Bournissen1,
  3. R Kim2,
  4. U I Schwarz2,
  5. P C Nathan3,
  6. S Ito1
  1. 1
    Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada
  2. 2
    Clinical Pharmacology, Department of Medicine, University of Western Ontario Schulich School of Medicine & Dentistry, London, Canada
  3. 3
    Haematology and Oncology, The Hospital for Sick Children, Toronto, Canada
  1. Correspondence to Shinya Ito, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G 1X8, Canada; shinya.ito{at}sickkids.ca

Abstract

Genetic polymorphisms of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1), and SLCO1B1 coding organic anion-transporter polypeptide 1B1, are independent risk factors known to increase irinotecan toxicity in adults. Although combined occurrence of polymorphisms in these 2 genes is likely to influence susceptibility to irinotecan toxicity, data are scarce, especially in children. We report an 11-year-old female with severe and prolonged neutropenia after irinotecan-based chemotherapy. The patient’s genotyping revealed polymorphisms in both UGT1A1 and SLCO1B1. To our knowledge, this is the first case report of combined genotyping of both UGT1A1 and SLCO1B1 in a child with severe irinotecan toxicity.

https://doi.org/10.1136/adc.2009.163089

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • SS and F G-B contributed equally.

    • Funding SS and FG-B are supported by the Canadian Pharmacogenomics Network for Drug Safety. FG-B is also supported by the Clinician-Scientist training programme at the Hospital for Sick Children.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.